HIV antiretroviral agents inhibit protein synthesis and decrease ribosomal protein S6 and 4EBP1 phosphorylation in C2C12 myocytes.
Combined antiretroviral drug regimens have promoted clinical, immunologic, and virologic improvements in AIDS patients. Nevertheless, these therapies are associated with derangements in lipid and carbohydrate metabolism. In this study, we examined the effects of a representative protease inhibitor (nelfinavir), a nonnucleoside reverse transcriptase inhibitor (nevirapine), and a nucleoside reverse transcriptase inhibitor (zidovudine) on protein synthesis in skeletal muscle cells. To examine these processes, C2C12 myocytes were treated with increasing concentrations of nelfinavir, nevirapine, or zidovudine for 1 or 2 days, and rates of protein synthesis were determined by measuring [35S]methionine/cysteine incorporation into cellular proteins. Treatment of myocytes with therapeutic concentrations of nelfinavir, nevirapine, or zidovudine for 48 hr decreased protein synthesis by 14-20%. An approximately 60% decline was observed in cells treated with higher concentrations of nevirapine or nelfinavir. In contrast, the basal rate of protein synthesis was not affected when cells were incubated with these compounds for 24 hr. Therapeutic concentrations of nelfinavir and nevirapine did not impair the anabolic effect of insulin on protein synthesis. However, zidovudine suppressed the stimulatory effect of insulin. The decreased protein synthesis induced by nelfinavir and zidovudine was associated with decreases in the phosphorylation of the S6 ribosomal protein (rpS6) and the repressor binding protein 4EBP1, while the inhibitory effect of nevirapine was mainly associated with a decline in phosphorylated 4EBP1. In conclusion, nelfinavir, nevirapine, and zidovudine treatments decreased protein synthesis in myocytes and this effect was correlated with a reduction in the phosphorylation level of proteins that regulate translation initiation.
Hong-Brown
Ly Q
LQ
Department of Cellular and Molecular Physiology (H166), Penn State University College of Medicine, Hershey, PA 17033, USA. lqh10@psu.edu
Brown
C Randell
CR
Lang
Charles H
CH
D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology*; D002460:Cell Line; D051379:Mice; D032342:Muscle Cells / Q000187:drug effects* / Q000378:metabolism; D019888:Nelfinavir / Q000494:pharmacology*; D019829:Nevirapine / Q000494:pharmacology*; D010766:Phosphorylation; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology*; D038601:Ribosomal Protein S6 / Q000378:metabolism*; D015215:Zidovudine / Q000494:pharmacology*
D019380:Anti-HIV Agents; D011500:Protein Synthesis Inhibitors; D038601:Ribosomal Protein S6; D015215:Zidovudine; D019829:Nevirapine; D019888:Nelfinavir